Head-to-Head

Caris Life Sciences, Inc. Common Stock vs. Veracyte, Inc.

CAI

Caris Life Sciences, Inc. Common Stock

$31.75 -0.72%

VS VCYT

Veracyte, Inc.

$44.19 -4.02%

Caris Life Sciences, Inc. Common Stock (CAI) comes out ahead, leading on 5 of 9 compared factors.

Size & Scale

CAIVCYT
Market Cap $8.97 billion $3.70 billion
Revenue (TTM) $989.61 million $561.90 million
Net Income (TTM) $105.14 million $114.48 million

CAI leads on 2 of 3 size & scale factors.

Valuation

CAIVCYT
P/E Ratio 18.79 31.56
Price / Book 15.16 2.67
Price / Sales 9.07 6.59

VCYT leads on 2 of 3 valuation factors.

Profitability

CAIVCYT
Net Margin 10.62% 20.37%
Return on Equity 17.77% 8.25%

CAI and VCYT split the profitability factors evenly.

Dividend

CAIVCYT
Dividend Yield 3.78% —
Payout Ratio 71.01 —

CAI and VCYT split the dividend factors evenly.

Risk & Sentiment

CAIVCYT
Short Interest 0.13% 0.83%

CAI leads on 1 of 1 risk & sentiment factors.

Dig deeper: CAI overview, CAI financials, VCYT overview, VCYT financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.